Last updated: 2026-09-09 08:42:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Palvella Therapeutics, Inc. (PVLA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $151.99, with a market capitalization of $2.27B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $53.30 to $161.38. This page covers its latest market performance, valuation, price trends and company information.
$2.27B | |
$153.42 | |
$161.38 | |
$11.17 | |
$157.24 | |
142.91K | |
242.21K | |
-- | |
$161.38 | |
$53.30 | |
-- | |
-- |
Palvella Therapeutics, Inc. (PVLA) is trading at $155.50 in pre-market trading as of 2026-09-08 23:31:00, down 1.11% ($1.75) from the previous close of $157.24
Pre-market trading shows how investors are pricing PVLA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Palvella Therapeutics, Inc. (PVLA) moved from $149.97 to $151.99, representing a gain of 1.35% ($2.02).
The stock traded between $143.47 and $158.46 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 179.99 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 91.3%
PVLA is currently trading at $151.99, placing it 91.3% of the way from its 52-week low of $53.30 to its 52-week high of $161.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Palvella Therapeutics, Inc. (PVLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.